Regeneron Pharmaceuticals (REGN) has put its early liver disease program in the spotlight after first in human data showed that a single CIDEBsiRNA dose reduced liver fat and improved injury markers ...
Source LinkRegeneron Pharmaceuticals (REGN) has put its early liver disease program in the spotlight after first in human data showed that a single CIDEBsiRNA dose reduced liver fat and improved injury markers ...
Source Link
Comments